top of page


News

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 2, 2025 – Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy...
4 days ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
- Interim results from three trials exploring the use of Alpha DaRT ® in treating pancreatic cancer showing high disease control rate,...
Mar 13

Alpha Tau to Participate in March Investor Conferences
JERUSALEM, February 27, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Feb 27

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
Feb 24
bottom of page